PEMBROKE, Bermuda, Nov. 13, 2017 -- James River Group Holdings, Ltd. (NASDAQ:JRVR) (“James River” or the “Company”) announced today the closing of the previously announced underwritten secondary public offering of the Company’s common shares by certain of the Company’s shareholders (the “Selling Shareholders”). The Selling Shareholders sold an aggregate of 3,000,000 common shares for total net proceeds of $114,300,000. The Selling Shareholders received all of the net proceeds from this offering. The underwriter has a 30-day option to purchase up to an additional 450,000 common shares from certain of the Selling Shareholders. The Company did not sell any common shares in this transaction.
Morgan Stanley acted as the sole underwriter in the offering.
The Company has filed two registration statements, each including a prospectus, with the U.S. Securities and Exchange Commission (the “SEC”) for the offering to which this communication relates, which registration statements are effective. A copy of the final prospectus supplement relating to the offering was filed with the SEC on November 13, 2017. The offering was made only by means of a prospectus supplement and the accompanying prospectuses. You may obtain these documents for free by visiting EDGAR on the SEC’s website at www.sec.gov. Alternatively, copies of the prospectuses and accompanying prospectus supplement may be obtained from Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, New York 10014, Attention: Prospectus Department.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any state or jurisdiction.
Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. In some cases, such forward-looking statements may be identified by terms such as believe, expect, seek, may, will, intend, project, anticipate, plan, estimate or similar words. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These forward-looking statements speak only as of the date of this release and the Company does not undertake any obligation to update or revise any forward-looking information to reflect changes in assumptions, the occurrence of unanticipated events, or otherwise.
About the Company
James River Group Holdings, Ltd. is a Bermuda-based insurance holding company which owns and operates a group of specialty insurance and reinsurance companies. The Company operates in three specialty property-casualty insurance and reinsurance segments: Excess and Surplus Lines, Specialty Admitted Insurance and Casualty Reinsurance. The Company is headquartered in Pembroke, Bermuda.
Contact: James River Group Holdings, Ltd. Kevin Copeland 441-278-4573 [email protected]


Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 



